---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-039269"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2024-10-03T23:59:59+00:00"
generated_at: "2026-05-30T21:34:39.416007+00:00"
event_type: "other"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Oncocyte raises $10.2M in private placement, adds two major transplant centers as customers

## Summary
- Private placement of 3.46M shares at $2.948/share raises ~$10.2M gross; includes participation from strategic partner Bio-Rad.
- Proceeds for working capital and general corporate purposes; closing expected October 4, 2024.
- Two leading transplant university hospitals in U.S. and Germany adopt GraftAssure research assay for graft damage monitoring.
- Submitted Q-Sub to FDA for IVD version of dd-cfDNA test; FDA meeting scheduled for early December 2024.

## SEC filing metadata
- accession: 0001493152-24-039269
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2024-10-03T23:59:59+00:00
- event_type: other
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315224039269/0001493152-24-039269-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315224039269/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-039269
- JSON: https://secwatch.observer/filing/0001493152-24-039269.json
- Plain text: https://secwatch.observer/filing/0001493152-24-039269.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.